Latest Biological target Stories
Structures of human P2Y12 receptor key to next generation of antithrombotic drugs SHANGHAI, April 30, 2014 /PRNewswire/ -- An international team led by scientists at the Shanghai Institute
A receptor found on blood platelets whose importance as a potential pharmaceutical target has long been questioned may in fact be fruitful in drug testing, according to new research from Michigan State University chemists.
Researchers at the University of California, San Diego and Hunter College of the City University of New York (CUNY) have identified potential human molecular targets of the anti-HIV drug Nelfinavir, which may explain why the drug is also effective as a cancer therapy.
Potential molecular targets of the anti-HIV drug nelfinavir have been identified, and may explain why the drug is also effective as a cancer therapy.
Avila Therapeuticsâ„¢, Inc., a biotechnology company developing novel targeted covalent drugs, today announced the publication of a scientific review article in Nature Reviews Drug Discovery titled "The Resurgence of Covalent Drugs" (www.nature.com/reviews/drugdisc, Vol. 10, April 2011, Singh, J.).
Avila Therapeuticsâ„¢, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
Studies led by Stony Brook University professor of chemistry Peter J Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.
- A trick or prank.